Trecondi

Trecondi is a medicine given to patients before they have a bone marrow transplant from a donor known as ‘allogeneic haematopoietic stem cell transplantation’. It is used as a ‘conditioning’ treatment to clear the patient’s bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells. Trecondi is used together with a medicine called fludarabine in adults and children from 1 month of age with blood cancers or other severe disorders requiring a bone marrow transplant. The active substance in Trecondi is treosulfan. Haematopoietic stem cell transplantation is rare, and Trecondi was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 23 February 2004.